This company is no longer active
Selectimmune Pharma Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Gabriela Godaly
Chief executive officer
kr265.3k
Total compensation
| CEO salary percentage | 100.0% |
| CEO tenure | 1.3yrs |
| CEO ownership | n/a |
| Management average tenure | no data |
| Board average tenure | 5.6yrs |
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2023 | n/a | n/a | -kr9m |
| Dec 31 2022 | n/a | n/a | -kr9m |
| Sep 30 2022 | n/a | n/a | -kr12m |
| Jun 30 2022 | kr265k | kr265k | -kr14m |
| Mar 31 2022 | n/a | n/a | -kr16m |
| Dec 31 2021 | n/a | n/a | -kr15m |
| Sep 30 2021 | n/a | n/a | -kr14m |
| Jun 30 2021 | kr236k | kr236k | -kr13m |
| Mar 31 2021 | n/a | n/a | -kr9m |
| Dec 31 2020 | n/a | n/a | -kr9m |
| Sep 30 2020 | n/a | n/a | -kr8m |
| Jun 30 2020 | kr14k | n/a | -kr8m |
Compensation vs Market: Gabriela's total compensation ($USD24.78K) is below average for companies of similar size in the Swedish market ($USD229.96K).
Compensation vs Earnings: Gabriela's compensation has increased whilst the company is unprofitable.
CEO
Gabriela Godaly
1.3yrs
Tenure
kr265,250
Compensation
Dr. Gabriela Godaly serves as a Board Member of Selectimmune Pharma AB (publ) since 2019 and serves as its Chief Medical Officer since 2020 and as its Acting Chief Executive Officer since April 26, 2022. S...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Acting CEO | 4.6yrs | kr265.25k | no data | |
| Chairperson of the Board | 6.6yrs | kr360.00k | 40.59% SEK 16.9m | |
| Board Member | 5.6yrs | no data | no data | |
| Board Member | 6.6yrs | no data | 1.29% SEK 537.2k | |
| Board Member | less than a year | no data | no data |
5.6yrs
Average Tenure
Experienced Board: SELECT B's board of directors are considered experienced (5.6 years average tenure).